12 April 2016 - PHARMAC is pleased to announce a decision to list cinacalcet hydrochloride (Sensipar) on the Pharmaceutical Schedule through an agreement with Amgen Australia Pty Limited.

Sensipar will be listed in the Schedule from 1 May 2016 for:

• Patients with parathyroid carcinoma with symptomatic hypercalcaemia resistant to bisphosphonates and sodium thiosulfate, subject to Special Authority criteria
• Patients with symptomatic calciphylaxis after failure of bisphosphonates and sodium thiosulfate, subject to Special Authority criteria

This was the subject of a consultation letter dated 11 March 2016 that can be found on PHARMAC’s website.

The proposal was approved as consulted on with no changes except that the wastage rule will be applied to the listing of cinacalcet from 1 May 2016.

For more details, go to: http://www.pharmac.govt.nz/news/notification-2016-04-12-cinacalcet/